Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
This study is currently recruiting participants.
Verified April 2013 by Van Andel Research Institute
Study NCT00601003   Information provided by Van Andel Research Institute

First Received on January 14, 2008.   Last Updated on April 5, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neuroblastoma
Medulloblastoma
More general conditions related to this trial
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Interventions listed in this trial
Nifurtimox
Cyclophosphamide
Topotecan
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antiparasitic Agents
Antiprotozoal Agents
Antirheumatic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Trypanocidal Agents
Sponsors listed in this trial
Giselle Sholler
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services